(Total Views: 504)
Posted On: 05/18/2022 3:59:46 PM
Post# of 154090
Speaking of events...I pulled this at 9:17 this morning...from my newfound friends at ASCO... "Numerous challenges have disrupted accruals to Oncology trials over the past two years, given the COVID-19 Pandemic.
Seventeen hundred and forty-four drug shortages have happened since 2011 and 57% of medications involved are sterile injectable medications used in acute care settings.
In centers authorized to administer Chimeric Antigen receptor T-Cell (CAR-T) therapies, the emergence of Tocilizumab shortage since August 2021 has led to significant challenges in scheduling patients for potentially life-saving treatments.
The Delta Variant surge in August/September 2021 led to an unforeseen demand for this therapy... despite its vital use for managing CYTOKINE release syndrome following CAR-T therapies.
Given... the FDA Evaluation and Mitigation Strategies Program...requires CAR-T centers to have a minimum of two doses of Tocililumab for each patient undergoing CAR-T. This shortage has led to delays in therapies....CAN anyone say LERONLIMAB?
Seventeen hundred and forty-four drug shortages have happened since 2011 and 57% of medications involved are sterile injectable medications used in acute care settings.
In centers authorized to administer Chimeric Antigen receptor T-Cell (CAR-T) therapies, the emergence of Tocilizumab shortage since August 2021 has led to significant challenges in scheduling patients for potentially life-saving treatments.
The Delta Variant surge in August/September 2021 led to an unforeseen demand for this therapy... despite its vital use for managing CYTOKINE release syndrome following CAR-T therapies.
Given... the FDA Evaluation and Mitigation Strategies Program...requires CAR-T centers to have a minimum of two doses of Tocililumab for each patient undergoing CAR-T. This shortage has led to delays in therapies....CAN anyone say LERONLIMAB?
(6)
(0)
